PDGFRB and neoplasm: This drug has also demonstrated a significant reduction of gadolinium extravasation in rat glioblastoma tumor xenograft in preclinical studies, with antitumor activity and inhibition of tumor growth through the reduction of vascularization and the inhibition of the PDGFR pathway [15,16].